nach oben

International Journal of Hematology

Erschienen in:

01.05.2015 | Progress in Hematology

Therapeutic benefits targeting B-cells in chronic graft-versus-host disease

verfasst von: Hideki Nakasone, Bita Sahaf, David B. Miklos

Erschienen in: International Journal of Hematology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) can be a curative strategy for hematological diseases, and the indications for allo-HCT have broadened widely due to recent progress in supportive strategies. However, patients must overcome various complications and chronic graft-versus-host disease (cGVHD) remains the most common allo-HCT cause of long-term morbidity and mortality. cGVHD is difficult to biologically assess due to the heterogeneity of cGVHD symptoms, and the pathogenesis of cGVHD has yet to be established. Recent experimental model progress has suggested that B-cells play a critical role in cGVHD development. Consistent with these experimental results, some clinical studies investigating B-cell depletion and modulation of B-cell signaling pathways have decreased cGVHD incidence and provided some therapeutic benefit. However, randomized control studies are necessary to confirm the efficacy of B-cell targeting drugs for cGVHD. Here, we review the pathophysiology of cGVHD, especially focusing on the role of B-cell immunity, and discuss the efficacy of both B-cell depletion and modulation of B-cell signaling pathways in human cGVHD prevention, initial treatment, and salvage treatment.

Powles R. 50 years of allogeneic bone-marrow transplantation. Lancet Oncol. 2010;11(4):305–6.PubMed

Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617–24.PubMedCentralPubMed

Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114(3):702–8.PubMedCentralPubMed

Thepot S, Zhou J, Perrot A, et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010;24(11):1852–8.PubMed

Cho BS, Min CK, Eom KS, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia. 2009;23(1):78–84.PubMed

Kanda J, Nakasone H, Atsuta Y, et al. Risk factors and organ involvement of chronic GVHD in Japan. Bone Marrow Transpl. 2014;49(2):228–35.

Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2015;21(2):266–74.

Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124(3):374–84.PubMed

Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114(1):7–19.PubMedCentralPubMed

10.

Pidala J, Vogelsang G, Martin P, et al. Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a chronic graft-versus-host disease consortium study. Haematologica. 2012;97(3):451–8.PubMedCentralPubMed

11.

Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 2009;114(24):4919–27.PubMed

12.

Ratanatharathorn V, Pavletic S, Uberti JP. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects. Cancer Treat Rev. 2009;35(8):653–61.PubMed

13.

Srinivasan M, Flynn R, Price A, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119(6):1570–80.PubMedCentralPubMed

14.

Sarantopoulos S, Blazar BR, Cutler C, Ritz J. B cells in chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2015;21(1):16–23.

15.

Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma. 2010;51(3):376–89.PubMed

16.

Kharfan-Dabaja MA, Cutler CS. Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol. 2011;93(5):578–85.PubMed

17.

Arai S, Miklos DB. Rituximab in hematopoietic cell transplantation. Expert Opin Biol Ther. 2010;10(6):971–82.PubMed

18.

Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2003;9(4):215–33.

19.

Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21(3):389–401.

20.

Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–9.PubMedCentralPubMed

21.

Inamoto Y, Flowers ME. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol. 2011;18(6):414–20.PubMedCentralPubMed

22.

Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11(12):945–56.

23.

Nakasone H, Onizuka M, Suzuki N, et al. Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation. Bone Marrow Transpl. 2013;48(10):1317–23.

24.

Nakasone H, Ito A, Endo H, Kida M, Koji I, Usuki K. Pancreatic atrophy is associated with gastrointestinal chronic GVHD following allogeneic PBSC transplantation. Bone Marrow Transpl. 2010;45(3):590–2.

25.

Brook OR, Mullan CP, Mendiratta-Lala M, et al. Pancreatic atrophy in patients with chronic graft-versus-host disease. Abdom Imaging. 2014;39(2):342–7.PubMed

26.

Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009;302(3):306–14.PubMed

27.

Nakasone H, Kanda J, Yano S, et al. A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. Transpl Int. 2013;26(6):631–9.PubMed

28.

Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2010;16(1 Suppl):S106–14.

29.

Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61.PubMedCentralPubMed

30.

Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412–5.PubMed

31.

Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8(6):575–81.PubMed

32.

Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90(8):3204–13.PubMed

33.

Hill GR, Teshima T, Rebel VI, et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol. 2000;164(2):656–63.PubMed

34.

Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95(9):2754–9.PubMed

35.

Nakasone H, Fukuda T, Kanda J, et al. Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. Bone Marrow Transpl. 2014. doi:10.1038/bmt.2014.293.

36.

Kanda J, Lopez RD, Rizzieri DA. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol. 2011;93(5):586–93.PubMed

37.

Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009;114(5):1099–109.PubMedCentralPubMed

38.

Olivieri J, Coluzzi S, Attolico I, Olivieri A. Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside. Sci World J. 2011;11:1908–31.

39.

Chu YW, Gress RE. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transpl. 2008;14(4):365–78.

40.

Blazar B, White ES, Couriel D. Understanding chronic GVHD from different angles. Biol Blood Marrow Transpl. 2012;18(1 Suppl):S184–8.

41.

Wu T, Young JS, Johnston H, et al. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells. J Immunol. 2013;191(1):488–99.PubMedCentralPubMed

42.

Flynn R, Du J, Veenstra RG, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014;123(25):3988–98.PubMed

43.

Alexander KA, Flynn R, Lineburg KE, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest. 2014;124(10):4266–80.PubMedCentralPubMed

44.

Young JS, Wu T, Chen Y, et al. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol. 2012;189(1):222–33.PubMedCentralPubMed

45.

Zhao D, Young JS, Chen YH, et al. Alloimmune response results in expansion of autoreactive donor CD4+ T cells in transplants that can mediate chronic graft-versus-host disease. J Immunol. 2011;186(2):856–68.PubMedCentralPubMed

46.

Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transpl. 2006;12(2):126–37.

47.

Khoder A, Sarvaria A, Alsuliman A, et al. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014;124(13):2034–45.PubMedCentralPubMed

48.

Matsuoka K, Kim HT, McDonough S, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010;120(5):1479–93.PubMedCentralPubMed

49.

Kitko CL, Levine JE, Storer BE, et al. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood. 2014;123(5):786–93.PubMedCentralPubMed

50.

Nakasone H, Binh PN, Yamazaki R, et al. Association between serum high-molecular-weight adiponectin level and the severity of chronic graft-versus-host disease in allogeneic stem cell transplantation recipients. Blood. 2011;117(12):3469–72.PubMed

51.

Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2973–8.PubMedCentralPubMed

52.

Popli R, Sahaf B, Nakasone H, Lee JY, Miklos DB. Clinical impact of H-Y alloimmunity. Immunol Res. 2014;58(2–3):249–58.PubMedCentralPubMed

53.

Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110(1):237–41.PubMed

54.

Kuzmina Z, Gounden V, Curtis L, et al. Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. Am J Hematol. 2015;90(2):114–9.PubMed

55.

Boukouaci W, Busson M, Peffault de Latour R, et al. MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease. Blood. 2009;114(25):5216–24.PubMed

56.

Elfenbein GJ, Anderson PN, Humphrey RL, et al. Immune system reconstitution following allogeneic bone marrow transplantation in man: a multiparameter analysis. Transpl Proc. 1976;8(4):641–6.

57.

Noel DR, Witherspoon RP, Storb R, et al. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. Blood. 1978;51(6):1087–105.PubMed

58.

Frangoul H, Min E, Wang W, et al. Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT. Bone Marrow Transpl. 2013;48(11):1456–9.

59.

Müller AM, Linderman JA, Florek M, Miklos D, Shizuru JA. Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proc Natl Acad Sci USA. 2010;107(33):14721–6.PubMedCentralPubMed

60.

Sarantopoulos S, Ritz J. Aberrant B cell homeostasis in chronic GVHD. Blood. 2015;125(11):1703–7.PubMed

61.

Nakasone H, Tian L, Sahaf B, et al. Allogeneic HY antibodies 3 months following female to male sex-mismatched HCT predicts chronic GVHD and non-relapse mortality. Blood. 2015 [Epub ahead of print].

62.

Sahaf B, Yang Y, Arai S, Herzenberg LA, Miklos DB. H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. Proc Natl Acad Sci USA. 2013;110(8):3005–10.PubMedCentralPubMed

63.

Zhang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006;107(7):2993–3001.PubMed

64.

Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007;13(20):6107–14.PubMedCentralPubMed

65.

Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113(16):3865–74.PubMedCentralPubMed

66.

Allen JL, Tata PV, Fore MS, et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood. 2014;123(13):2108–15.PubMedCentralPubMed

67.

Allen JL, Fore MS, Wooten J, et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood. 2012;120(12):2529–36.PubMedCentralPubMed

68.

Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756–62.PubMedCentralPubMed

69.

Ratanatharathorn V, Logan B, Wang D, et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol. 2009;145(6):816–24.PubMedCentralPubMed

70.

van Dorp S, Pietersma F, Wölfl M, et al. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol Blood Marrow Transpl. 2009;15(6):671–8.

71.

Arai S, Sahaf B, Narasimhan B, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012;119(25):6145–54.PubMedCentralPubMed

72.

Cutler C, Kim HT, Bindra B, et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013;122(8):1510–7.PubMedCentralPubMed

73.

Sahaf B, Arai S, Otani J, Schoenrock K, Logan A, Miklos DB. Rituximab provides steroid-sparing therapy in new-onset chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2013;19(2):S140 (Abstract 155).

74.

Cutler C, Kim HT, Bindra B, et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase II trial. Blood. 2013;122(8):1510-7.PubMedCentralPubMed

75.

Sauter CS, Barker JN, Lechner L, et al. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biol Blood Marrow Transpl. 2014;20(3):354–60.

76.

Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111(12):5530–6.PubMed

77.

Pidala J, Kim J, Yue B, et al. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft vs. host disease. Biol Blood Marrow Transpl. 2015;21(2):S343–S344 (Abstract 500).

78.

Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transpl. 2007;40(3):273–7.

79.

Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica. 2010;95(11):1935–42.PubMedCentralPubMed

80.

Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transpl. 2009;15(9):1005–13.

81.

Arai S, Pidala J, Pusic I, et al. A randomized phase II study of imatinib and rituximab for cutaneous sclerosis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2015;21(2):S324 (Abstract 469).

82.

Satterthwaite AB, Witte ON. The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175:120–7.PubMed

83.

Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94.PubMed

84.

Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.PubMedCentralPubMed

85.

Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes. Blood. 2013;122(15):2539–49.PubMedCentralPubMed

86.

Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14(4):219–32.PubMed

87.

Dubovsky JA, Flynn R, Du J, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014;124(11):4867–76.PubMedCentralPubMed

88.

Ryan C, Logan A, Rezvani A, et al. Ibrutinib treatment of relapsed CLL following allogeneic transplantation: sustained disease response and promising donor immune modulation. Biol Blood Marrow Transpl. 2015;21(S2):S307–8.

89.

Santachiara R, Maffei R, Martinelli S, et al. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. Haematologica. 2008;93(8):1252–5.PubMed

90.

de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122(2):227–38.PubMed

91.

Chen GL, Arai S, Flowers ME, et al. A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood. 2011;118(15):4070–8.PubMed

92.

Olivieri A, Cimminiello M, Corradini P, et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood. 2013;122(25):4111–8.PubMed

93.

Sánchez-Ortega I, Servitje O, Arnan M, et al. Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2012;18(2):318–23.

94.

Koreth J, Alyea EP, Murphy WJ, Welniak LA. Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review. Biol Blood Marrow Transpl. 2009;15(12):1502–12.

95.

Koreth J, Stevenson KE, Kim HT, et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012;30(26):3202–8.PubMedCentralPubMed

96.

Herrera AF, Kim HT, Bindra B, et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2014;20(11):1737–43.

97.

Pai CC, Chen M, Mirsoian A, et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood. 2014;124(10):1677–88.PubMed

98.

Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98(13):3595–9.PubMed

99.

100.

Olavarria E, Siddique S, Griffiths MJ, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood. 2007;110(13):4614–7.PubMed

101.

Nakasone H, Kanda Y, Takasaki H, et al. Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. Leukemia. 2010;24(6):1236–9.PubMed

102.

Caocci G, Vacca A, Ledda A, et al. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transpl. 2012;18(4):652–4.

103.

Zhao Y, Luo Y, Shi J, Cai Z, Huang H. Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia. Am J Med Sci. 2014;347(6):439–45.PubMed

104.

Shimoni A, Volchek Y, Koren-Michowitz M, et al. Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(6):863–71.PubMed

105.

Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood. 2009;114(3):719–22.PubMed

106.

Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709–18.PubMed

107.

de Masson A, Bouaziz JD, Peffault de Latour R, et al. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood. 2012;120(25):5089–90.PubMed

108.

Mateos-Mazon J, Pérez-Simón JA, Lopez O, Hernández E, Etxebarria J, San Miguel JF. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. Haematologica. 2007;92(9):1295–6.PubMed

Titel: Therapeutic benefits targeting B-cells in chronic graft-versus-host disease
verfasst von: Hideki Nakasone
Bita Sahaf
David B. Miklos
Publikationsdatum: 01.05.2015
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 5/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-015-1782-4

Springer Medizin

Therapeutic benefits targeting B-cells in chronic graft-versus-host disease

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Prophylactic and therapeutic treatment of graft-versus-host disease in Japan

Clinical significance of nontuberculous mycobacteria from respiratory specimens in stem cell transplantation recipients

Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation

Disappearance of double minute chromosomes with MYC amplification in relapsed acute myeloid leukemia after stem cell transplantation

State-of-the-art acute and chronic GVHD treatment

A case of clonally distinct relapse of Burkitt lymphoma 9 years after complete remission

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie